Targeted alpha therapy with the ²²⁴Ra/²¹²Pb-TCMC-TP-3 dual alpha solution in a multicellular tumor spheroid model of osteosarcoma.

ABSTRACT: Osteosarcoma patients with overt metastases at primary diagnosis have a 5-year survival rate of less than 20%. TP-3 is a murine IgG2b monoclonal antibody with high affinity for an epitope residing on the p80 osteosarcoma cell surface membrane antigen. The tumor-associated antigen p80 is overexpressed in osteosarcomas, and has very low normal tissue expression. We propose a novel dual alpha targeting solution containing two radionuclides from the same decay chain, including the bone-seeking ²²⁴Ra, and cancer cell-surface seeking ²¹²Pb-TCMC-TP-3 for the treatment of osteoblastic bone cancers, circulating cancer cells and micrometastases. In this in vitro study, the cytotoxic effects of ²¹²Pb-TCMC-TP-3 (single alpha solution) and ²²⁴Ra/²

SUBMITTER: Tornes AJK 

PROVIDER: S-EPMC9727293 | biostudies-literature | 2022

REPOSITORIES: biostudies-literature